

Karolinska Development AGM 2025: Information on candidates nominated for election or re-election to the board

Re-election

Ben Toogood

Board member since 2021. Chairman since 2024.

Born 1976. Bachelor of Pharmacy from Rhodes University. MSc. from University of Witwatersrand and Executive MBA from University of Cambridge.

Other appointments: Head Global Business Development, Sino Biopharmaceuticals Limited and CEO, invoX Pharma Limited.

Previous assignments: Head Global BD & M&A Sandoz AG, Group New Business Development Executive Aspen Pharmacare Holdings, Vice President Global Business Development Pharmathen SA, International Licensing Executive Niche Generics (Unichem Laboratories) and Regulatory Affairs Merck Generics (Mylan).

Independent in relation to the company and its executive management. Not independent in relation to the company's major shareholders.

Holdings in Karolinska Development: 64,001 shares.

Re-election

Anna Lefevre Skjöldebrand

Board member since 2021.

Born 1969. Master of Laws from Uppsala University.

Other appointments: CEO Swedish Medtech Service AB. Current board assignments include Sweden Medtech4Health AB (chairwoman) and Swecare.

Previous assignment: Head of Legal Swedish Medtech Service AB, Advokat Delphi & Co, Advokat GLS Legal, Jurist Ernst & Young Law, Legal Counsel Front Capital Systems AB.

Previous board assignments include Dedicare AB, E-hälsomyndigheten, SIS AB, Medtech Europe, St Eriks ögonsjukhus and COCIR, Life Science office of Sweden. She has also been a member of the board of the Board for Public Procurement.

Independent in relation to the company, its executive management and the company's major shareholders.

No holdings in Karolinska Development.

Re-election

Philip Duong

Board member since 2022.

Born 1990. Bachelor's degree of Commerce from University of Toronto.

Other appointments: Head of Overseas BD & Alliance at Sino Biopharmaceuticals Limited, member of the board at Treadwell Therapeutics.

Previous assignments: Deutsche Bank AG (Hong Kong Branch).

Independent in relation to the company and its executive management. Not independent in relation to the company's major shareholders.

No holdings in Karolinska Development.

Re-election

Will Zeng

Board member since 2024.

Born 1993. Bachelor's degree of Economics from the Wharton School of the University of Pennsylvania.

Other appointments: Finance Director of CTTQ Pharma Group and Special Assistant to the chairperson of the board of Sino Biopharmaceutical.

Previous assignments: Work at Goldman Sachs and Warburg Pincus.

Independent in relation to the company and its executive management. Not independent in relation to the company's major shareholders.

No holdings in Karolinska Development.

New election

Anders Härfstrand

Born 1956. MD. Ph.D from the Karolinska Institute.

Other appointments: Founder Härfstrand Consulting AG, Switzerland, Co- Founder P4BIOS, USA, Consultant to CIS Biopharma, Switzerland.

Previous assignments: Member of the executive management of Pharmacia, Pfizer-Japan and Serono, CEO for various European biotech companies, chairman of the board and board member of public and private companies in the USA and Europe. He has also been a former board member of Karolinska Development.

Independent in relation to the company, its executive management and the company's major shareholders.

No holdings in Karolinska Development.